8-K Announcements
6Material company update
Mar 10, 2026·SEC
Material company update
Feb 24, 2026·SEC
Material company update
Feb 19, 2026·SEC
Artiva Biotherapeutics, Inc.(ARTV)Earnings, Financials & Key Ratios
ARTV•NASDAQ
$12.52
$307M mkt cap·Price updated May 7, 2026
AboutArtiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Show more
- Revenue$251K-99.3%
- EBITDA-$65M-128.3%
- Net Income-$58M-111.2%
- EPS (Diluted)-5.20-337.0%
- Gross Margin100%
- EBITDA Margin-25837.05%-30364.2%
- Operating Margin-26805.58%-29171.0%
- Net Margin-23303.98%-28080.8%
- ROE-475.05%
- Debt/Equity0.08
ARTV Key Insights
Artiva Biotherapeutics, Inc. (ARTV) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 97 (top 3%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ARTV Price & Volume
Artiva Biotherapeutics, Inc. (ARTV) stock price & volume — 10-year historical chart
Loading chart...
ARTV Growth Metrics
Artiva Biotherapeutics, Inc. (ARTV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-49.95%
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-18%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-18.47%
Return on Capital
10 Years-52.48%
5 Years-52.48%
3 Years-41.12%
Last Year-46.37%
ARTV Recent Earnings
Artiva Biotherapeutics, Inc. (ARTV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (43%)
Q2 2026Latest
Mar 10, 2026EPS
$0.84
Est $0.87
+3.4%
Revenue
—
Q4 2025
Nov 12, 2025EPS
$0.88
Est $0.92
+4.3%
Revenue
—
Q3 2025
Aug 6, 2025EPS
$0.87
Est $0.84
-3.6%
Revenue
—
Q2 2025
May 8, 2025EPS
$0.83
Est $0.68
-22.1%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 10, 2026 | $0.84vs $0.87+3.4% | — |
| Q4 2025 | Nov 12, 2025 | $0.88vs $0.92+4.3% | — |
| Q3 2025 | Aug 6, 2025 | $0.87vs $0.84-3.6% | — |
| Q2 2025 | May 8, 2025 | $0.83vs $0.68-22.1% | — |
Based on last 12 quarters of dataView full earnings history →
ARTV Peer Comparison
Artiva Biotherapeutics, Inc. (ARTV) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 280.32M | 2.43 | -2.11 | -51.24% | -20.51% | -65.79% | 0.38 | |
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 STTK | 299.87M | 6.26 | -8.94 | -82.52% | -49.87% | -60.73% | 0.02 | |
 IOVA | 1.27B | 3.55 | -3.26 | 60.6% | -123.9% | -50.17% | 0.07 | |
 CRSP | 5.06B | 52.42 | -8.10 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.62B | 13.71 | -3.60 | 16.92% | -6.1% | -56.63% | 0.14 | |
 BEAM | 3.23B | 31.47 | -38.85 | 120.01% | -49.17% | -5.89% | 0.24 | |
 EDIT | 296.54M | 3.03 | -1.68 | -100% | -5.23% | 0.66 |
Compare ARTV vs Peers
Artiva Biotherapeutics, Inc. (ARTV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ARTV Income Statement
Artiva Biotherapeutics, Inc. (ARTV) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 2M | 4.93M | 33.49M | 251K | 0 |
| Revenue Growth % | - | - | 146.3% | 579.21% | -99.25% | -100% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 662K |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 2M▲ 0% | 4.93M▲ 146.3% | 33.49M▲ 579.2% | 251K▼ 99.3% | -662K▲ 0% |
| Gross Margin % | - | 100% | 100% | 100% | 100% | - |
| Gross Profit Growth % | - | - | 146.3% | 579.21% | -99.25% | - |
| Operating Expenses | 18.27M | 55.27M | 64.76M | 64.16M | 67.53M | 85.48M |
| OpEx % of Revenue | - | 2760.94% | 1313.32% | 191.58% | 26905.58% | - |
| Selling, General & Admin | 4.43M | 12.86M | 20.78M | 13.91M | 17.2M | 20.28M |
| SG&A % of Revenue | - | 642.56% | 421.33% | 41.54% | 6854.58% | - |
| Research & Development | 13.85M | 42.41M | 43.98M | 50.25M | 50.33M | 65.2M |
| R&D % of Revenue | - | 2118.38% | 891.99% | 150.04% | 20051% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -18.27M▲ 0% | -53.27M▼ 191.6% | -59.83M▼ 12.3% | -30.67M▲ 48.7% | -67.28M▼ 119.4% | -86.14M▲ 0% |
| Operating Margin % | - | -2660.94% | -1213.32% | -91.58% | -26805.58% | - |
| Operating Income Growth % | - | -191.57% | -12.31% | 48.74% | -119.37% | - |
| EBITDA | -18.2M | -53.02M | -58.67M | -28.41M | -64.85M | -83.6M |
| EBITDA Margin % | - | -2648.55% | -1189.84% | -84.81% | -25837.05% | - |
| EBITDA Growth % | - | -191.37% | -10.65% | 51.59% | -128.31% | -42.72% |
| D&A (Non-Cash Add-back) | 73K | 248K | 1.16M | 2.27M | 2.43M | 2.54M |
| EBIT | -17.59M | -71.83M | -59.83M | -30.67M | -67.28M | -84.78M |
| Net Interest Income | -197K | 0 | 1.29M | 2.54M | 5.35M | 6.97M |
| Interest Income | 2K | 0 | 1.29M | 2.54M | 5.35M | 6.97M |
| Interest Expense | 199K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 280K | -18.55M | 1.49M | 3.05M | 8.79M | 13.84M |
| Pretax Income | -17.99M▲ 0% | -71.83M▼ 299.2% | -58.34M▲ 18.8% | -27.62M▲ 52.6% | -58.49M▼ 111.7% | -72.31M▲ 0% |
| Pretax Margin % | - | -3587.66% | -1183.03% | -82.48% | -23303.98% | - |
| Income Tax | 0 | 0 | 53K | 72K | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | -0.09% | -0.26% | 0% | 0% |
| Net Income | -17.99M▲ 0% | -71.83M▼ 299.2% | -58.39M▲ 18.7% | -27.7M▲ 52.6% | -58.49M▼ 111.2% | -72.31M▲ 0% |
| Net Margin % | - | -3587.66% | -1184.1% | -82.69% | -23303.98% | - |
| Net Income Growth % | - | -299.23% | 18.71% | 52.57% | -111.2% | -18% |
| Net Income (Continuing) | -17.99M | -71.83M | -58.39M | -27.7M | -58.49M | -72.31M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.02▲ 0% | -4.08▼ 300.0% | -3.32▲ 18.6% | -1.19▲ 64.2% | -5.20▼ 337.0% | -2.95▲ 0% |
| EPS Growth % | - | -300% | 18.63% | 64.16% | -336.97% | -18.47% |
| EPS (Basic) | -1.02 | -4.08 | -3.32 | -1.19 | -5.20 | - |
| Diluted Shares Outstanding | 17.58M | 17.58M | 17.58M | 23.28M | 24.36M | 24.48M |
| Basic Shares Outstanding | 17.58M | 17.58M | 17.58M | 23.28M | 24.36M | 24.48M |
| Dividend Payout Ratio | - | - | - | - | - | - |
ARTV Balance Sheet
Artiva Biotherapeutics, Inc. (ARTV) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Total Current Assets | 26.11M | 162.29M | 104.67M | 79.82M | 188.63M | 129.52M |
| Cash & Short-Term Investments | 25.44M | 160.92M | 102.53M | 76.97M | 185.43M | 122.97M |
| Cash Only | 25.44M | 160.92M | 102.53M | 53.5M | 40.23M | 25.51M |
| Short-Term Investments | 0 | 0 | 0 | 23.47M | 145.19M | 97.46M |
| Accounts Receivable | 0 | 468K | 525K | 1.76M | 146K | 879K |
| Days Sales Outstanding | - | 85.32 | 38.86 | 19.16 | 212.31 | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 1.62M | 1.09M | 3.06M | 5.68M |
| Total Non-Current Assets | 3.13M | 7.64M | 28.37M | 25.29M | 20.95M | 19.34M |
| Property, Plant & Equipment | 2.39M | 4.08M | 27.61M | 24.64M | 20.43M | 18.46M |
| Fixed Asset Turnover | - | 0.49x | 0.18x | 1.36x | 0.01x | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 461K |
| Other Non-Current Assets | 732K | 3.56M | 762K | 650K | 525K | 1.92M |
| Total Assets | 29.23M▲ 0% | 169.93M▲ 481.3% | 133.05M▼ 21.7% | 105.11M▼ 21.0% | 209.58M▲ 99.4% | 148.86M▲ 0% |
| Asset Turnover | - | 0.01x | 0.04x | 0.32x | 0.00x | 0.00x |
| Asset Growth % | - | 481.26% | -21.7% | -21% | 99.38% | 300.65% |
| Total Current Liabilities | 5.76M | 19.3M | 25.63M | 12.23M | 12.25M | 11.12M |
| Accounts Payable | 2.15M | 1.44M | 1.1M | 614K | 1.12M | 848K |
| Days Payables Outstanding | - | - | - | - | - | 719.52 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 3.17M |
| Deferred Revenue (Current) | 0 | 7.29M | 10.89M | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 1.46M |
| Current Ratio | 4.53x | 8.41x | 4.08x | 6.53x | 15.39x | 15.39x |
| Quick Ratio | 4.53x | 8.41x | 4.08x | 6.53x | 15.39x | 15.39x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 45.04M | 239.48M | 248.13M | 254.9M | 10.69M | 8.52M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 1.66M | 1.31M | 15.96M | 13.32M | 10.61M | 38.99M |
| Deferred Tax Liabilities | 0 | 216.41M | 216.41M | 0 | 0 | 0 |
| Other Non-Current Liabilities | 43.38M | 81K | 115K | 241.59M | 73K | 73K |
| Total Liabilities | 50.8M | 258.78M | 273.75M | 267.13M | 22.94M | 19.64M |
| Total Debt | 2.12M | 1.74M | 19.45M | 16.91M | 14.35M | 11.69M |
| Net Debt | -23.33M | -159.18M | -83.08M | -36.59M | -25.88M | -13.82M |
| Debt / Equity | - | - | - | - | 0.08x | 0.08x |
| Debt / EBITDA | - | - | - | - | - | -0.14x |
| Net Debt / EBITDA | - | - | - | - | - | 0.17x |
| Interest Coverage | -91.81x | - | - | - | - | - |
| Total Equity | -21.57M▲ 0% | -88.86M▼ 312.0% | -140.7M▼ 58.3% | -162.01M▼ 15.2% | 186.64M▲ 215.2% | 129.22M▲ 0% |
| Equity Growth % | - | -312.01% | -58.34% | -15.15% | 215.2% | 554.11% |
| Book Value per Share | -1.23 | -5.05 | -8.00 | -6.96 | 7.66 | 5.28 |
| Total Shareholders' Equity | -21.57M | -88.86M | -140.7M | -162.01M | 186.64M | 129.22M |
| Common Stock | 0 | 0 | 0 | 0 | 3K | 3K |
| Retained Earnings | -21.98M | -93.8M | -152.59M | -181.31M | -246.68M | -309.78M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 308K | -129K | 87K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
ARTV Cash Flow Statement
Artiva Biotherapeutics, Inc. (ARTV) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Cash from Operations | -13.54M | -15.3M | -50.83M | -47.43M | -55.03M | -55.03M |
| Operating CF Margin % | - | -764.44% | -1030.81% | -141.62% | -21925.1% | - |
| Operating CF Growth % | - | -13.02% | -232.13% | 6.69% | -16.03% | -202.07% |
| Net Income | -17.99M | -71.83M | -58.79M | -28.72M | -65.37M | -72.31M |
| Depreciation & Amortization | 73K | 248K | 1.16M | 2.27M | 2.43M | 2.19M |
| Stock-Based Compensation | 297K | 4.31M | 6.58M | 7.05M | 6.98M | 7.42M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -278K | 18.55M | 4.08M | 251K | 1.25M | -6.78M |
| Working Capital Changes | 4.36M | 33.41M | -3.87M | -28.28M | -325K | -311K |
| Change in Receivables | 0 | -468K | -57K | -1.23M | 1.61M | 555K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.82M | -1.24M | 190K | -408K | 519K | -692K |
| Cash from Investing | -284K | -1.72M | -6.3M | -25.98M | -120.46M | 46.41M |
| Capital Expenditures | -284K | -1.72M | -6.3M | -3.26M | -642K | -2.23M |
| CapEx % of Revenue | - | 86.11% | 127.74% | 9.73% | 255.78% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 37.4M | 152.75M | -1.26M | 24.39M | 162.23M | 100K |
| Debt Issued (Net) | 3M | 0 | 0 | 0 | -149K | -99K |
| Equity Issued (Net) | 1000K | 1000K | -5K | -12K | 1000K | -1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -5K | -12K | -4.18M | -4.18M |
| Other Financing | -459K | -1.86M | -1.26M | 24.4M | 51K | 4.38M |
| Net Change in Cash | 23.57M▲ 0% | 135.73M▲ 475.8% | -58.39M▼ 143.0% | -49.01M▲ 16.1% | -13.27M▲ 72.9% | -30.17M▲ 0% |
| Free Cash Flow | -13.82M▲ 0% | -17.03M▼ 23.2% | -57.13M▼ 235.5% | -50.69M▲ 11.3% | -55.67M▼ 9.8% | -78.91M▲ 0% |
| FCF Margin % | - | -850.55% | -1158.55% | -151.34% | -22180.88% | - |
| FCF Growth % | - | -23.17% | -235.49% | 11.27% | -9.84% | -50.95% |
| FCF per Share | -0.79 | -0.97 | -3.25 | -2.18 | -2.29 | -2.29 |
| FCF Conversion (FCF/Net Income) | 0.75x | 0.21x | 0.87x | 1.71x | 0.94x | 1.09x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 83K | 0 | 0 |
ARTV Key Ratios
Artiva Biotherapeutics, Inc. (ARTV) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -475.05% | -55.96% |
| Return on Invested Capital (ROIC) | - | - | - | - | -45.96% |
| Gross Margin | 100% | 100% | 100% | 100% | - |
| Net Margin | -3587.66% | -1184.1% | -82.69% | -23303.98% | - |
| Debt / Equity | - | - | - | 0.08x | 0.08x |
| FCF Conversion | 0.21x | 0.87x | 1.71x | 0.94x | 1.09x |
| Revenue Growth | - | 146.3% | 579.21% | -99.25% | -100% |
ARTV SEC Filings & Documents
Artiva Biotherapeutics, Inc. (ARTV) SEC filings — annual & quarterly reports (10-K, 10-Q)
ARTV Frequently Asked Questions
Artiva Biotherapeutics, Inc. (ARTV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Artiva Biotherapeutics, Inc. (ARTV) reported $0.3M in revenue for fiscal year 2024.
Artiva Biotherapeutics, Inc. (ARTV) saw revenue decline by 99.3% over the past year.
Artiva Biotherapeutics, Inc. (ARTV) reported a net loss of $72.3M for fiscal year 2024.
Dividend & Returns
Artiva Biotherapeutics, Inc. (ARTV) has a return on equity (ROE) of -475.1%. Negative ROE indicates the company is unprofitable.
Artiva Biotherapeutics, Inc. (ARTV) had negative free cash flow of $78.9M in fiscal year 2024, likely due to heavy capital investments.
Explore More ARTV
Artiva Biotherapeutics, Inc. (ARTV) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates